Effect of Ospemifene on Densitometric and Plasma Bone Metabolism Biomarkers in Postmenopausal Women Reporting Vulvar and Vaginal Atrophy (VVA).

Published in: Journal of clinical medicine (2022)

Long-term OSP treatment improves bone mineral markers at TF and LS and slows bone loss at FN compared to the control group. Overall, OSP exerts a protective effect on bone loss in healthy menopausal women with VVA.

Keyphrases

bone loss
postmenopausal women
bone mineral density
adverse drug
squamous cell carcinoma
sentinel lymph node
lymph node